Overview of the Agent and Its Approved Indications
Risankizumab (Skyrizi; risankizumab-rzaa), a humanized IgG1 monoclonal antibody selectively neutralizing the p19 subunit of interleukin-23 (IL-23p19), is developed by AbbVie and approved for four distinct immune-mediated inflammatory diseases: moderate-to-severe plaque psoriasis, active psoriatic arthritis (PsA), moderately to severely active Crohn's disease (CD), and moderately to severely active ulcerative colitis (UC) in adults 3042. By targeting only the IL-23p19 subunit rather than the shared p40 subunit, risankizumab selectively inhibits the Th17/Th22 axis without disrupting IL-12–mediated immune surveillance, a mechanistic distinction that has translatable clinical consequences compared with dual IL-12/IL-23 blockade 5642. Pharmacokinetic analyses across all indications confirm linear and time-independent behavior consistent with a typical IgG1 antibody, with an absolute subcutaneous bioavailability of 74–89%, steady-state terminal half-life of approximately 26.3 days in PsA patients, and no clinically meaningful covariate effects on exposure 3942.
Dosing Regimens and Administrative Complexity
A critical practical consideration is that dosing regimens differ substantially across indications, creating specialty-specific implementation challenges. In plaque psoriasis and PsA, risankizumab is administered as a 150 mg subcutaneous injection at weeks 0 and 4, then every 12 weeks, enabling patient self-injection after training 3037. In Crohn's disease, induction requires intravenous infusion of 600 mg at weeks 0, 4, and 8, followed by subcutaneous maintenance of 180 mg or 360 mg every 8 weeks; in UC, induction is 1,200 mg intravenously at the same schedule, followed by identical subcutaneous maintenance options 3031. The intravenous induction phase necessitates infusion center capacity and healthcare provider administration, with prepared solutions stable for up to 20 hours refrigerated or 8 hours at room temperature, introducing clinic workflow considerations that do not apply to the dermatology/rheumatology subcutaneous-only formulations 30.
Efficacy by Indication
Plaque Psoriasis
The phase 3 UltIMMa-1 and UltIMMa-2 trials (NCT02684370, NCT02684357) enrolled 506 and 491 patients, respectively, across 139 sites in 14 countries and established risankizumab's superiority over both placebo and ustekinumab as a primary comparator 2. At week 16, PASI 90 response rates were 75.3% and 74.8% for risankizumab versus 42.0% and 47.5% for ustekinumab (p<0.0001 in both trials), with static Physician's Global Assessment (sPGA) 0/1 achieved by 87.8% and 83.7% of risankizumab patients 2. The earlier phase 2 head-to-head trial (NCT02054481) had demonstrated PASI 90 in 77% of pooled risankizumab recipients versus 40% for ustekinumab, and complete clearance (PASI 100) in 45% versus 18% 1. Safety in both trials was comparable across treatment arms, with treatment-emergent adverse events (TEAEs) occurring in 45.6–49.7% of risankizumab patients, broadly similar to placebo and ustekinumab, with no unexpected signals 2. Long-term safety data further support a favorable profile with no new signals through extended follow-up 1548.
Psoriatic Arthritis
The KEEPsAKE 1 (NCT03675308) and KEEPsAKE 2 (NCT03671148) pivotal trials evaluated risankizumab in csDMARD-inadequate responders (KS1) and biologic-experienced patients (KS2), with long-term extension data now available through week 196 40. At week 196, approximately 57% of continuous risankizumab patients in KS1 and 55% in KS2 maintained ACR20 response, and Minimal Disease Activity (MDA) was achieved in approximately 37–40% across arms. Response maintenance from week 52 through week 196 exceeded 70% for ACR20 in both studies, confirming durable efficacy 40. Pharmacokinetic-exposure analyses from 1,407 PsA patients confirmed that the approved 150 mg SC regimen maximized ACR20/50/70 and MDA responses without exposure-dependent safety signals 39. The ACR and NICE have specifically recognized risankizumab for active PsA with DMARD inadequate response, and the 2024 Chinese guideline positions IL-23 inhibitors alongside IL-17A, IL-12/23, and TNF inhibitors as equivalent options for PsA (Recommendation Strength: C) 222737.
Crohn's Disease
In the ADVANCE (NCT03105128) and MOTIVATE (NCT03104413) phase 3 induction trials, risankizumab met co-primary endpoints of CDAI clinical remission, patient-reported symptom remission, and endoscopic response at week 12 versus placebo (all p≤0.0001) 3. CDAI clinical remission rates were 42–45% for risankizumab 600 mg versus 20–25% for placebo, and endoscopic response was achieved in 29–40% of risankizumab patients versus 11–12% for placebo across the two trials 3. The phase 2 open-label extension (NCT02031276) demonstrated that 53% of risankizumab-re-treated patients achieved CDAI remission at week 26, rising to 71% at week 52 maintenance with 35% achieving endoscopic remission 4. The AGA Living Guideline now explicitly recommends risankizumab as one of the biologic options for moderate-to-severe CD alongside infliximab, adalimumab, ustekinumab, mirikizumab, and guselkumab 23.
Ulcerative Colitis
The UC induction (NCT03398148) and maintenance phase 3 trials enrolled 977 and 754 patients respectively across 37–41 countries 41. Risankizumab 1,200 mg IV induction achieved clinical remission in 20.3% of patients versus 6.2% for placebo at week 12 (adjusted difference 14.0%; 95% CI 10.0–18.0%; p<0.001) 41. In the maintenance trial, clinical remission at week 52 was achieved by 40.2% (180 mg SC) and 37.6% (360 mg SC) versus 25.1% for placebo, with both doses statistically superior 41. No new safety risks were identified in either trial 41.
Comparative Efficacy Summary Table
| Indication | Key Trial(s) | Primary Endpoint | Risankizumab Result | Active Comparator Result | Placebo Result |
|---|---|---|---|---|---|
| Plaque Psoriasis | UltIMMa-1/2 2 | PASI 90 at Week 16 | 74.8–75.3% | 42.0–47.5% (ustekinumab) | 2.0–4.9% |
| Psoriatic Arthritis | KEEPsAKE 1/2 through Wk 196 40 | ACR20 at Wk 196 | ~54–57% | — | ~(baseline) |
| Crohn's Disease | ADVANCE/MOTIVATE 3 | CDAI remission at Wk 12 | 42–45% (600 mg) | — | 20–25% |
| Ulcerative Colitis | Phase 3 Induction/Maintenance 41 | Clinical remission Wk 52 | 37.6–40.2% | — | 25.1% |
Safety Profile in the Context of Class Comparators
Across all four indications, risankizumab's safety profile is consistently favorable relative to placebo and active comparators. In a meta-analysis of 51 RCTs evaluating biologics in psoriasis, anti-IL-23 agents demonstrated a serious adverse event risk ratio of 0.95 (95% CI 0.59–1.52) versus placebo—the only biologic class showing no increase in SAE risk, compared to risk ratios of 1.68 for anti-TNF-alpha and 1.28 for anti-IL-17 agents 48. Tuberculosis reactivation risk is managed through mandatory pre-treatment screening; in phase 3 psoriasis trials, 72 subjects with latent TB received concurrent risankizumab and TB prophylaxis without any active TB case during a mean follow-up of 61 weeks 30. Unlike IL-17A inhibitors (secukinumab, ixekizumab, bimekizumab), risankizumab does not appear to carry a class-level risk of IBD exacerbation, making it particularly valuable in patients with psoriasis or PsA and concurrent IBD—a population identified as having substantially elevated IBD risk (psoriasis–CD odds ratio 1.70; psoriasis–UC odds ratio 1.75) 89. Immunogenicity to risankizumab has no major clinically relevant consequences for efficacy or safety across indications 42. Hepatic monitoring (liver enzymes and bilirubin at baseline and through at least 12 weeks of induction) is required specifically for the IBD indications 31. Risankizumab has not been formally studied in pregnancy, and live vaccines are contraindicated during therapy 3037.
Compared with the dual IL-17A/F inhibitor bimekizumab—which achieved ACR50 of 61–66% in phase 2b PsA data (BE ACTIVE; NCT02969525) 7—risankizumab's class advantage lies in the absence of Candida-associated mucosal adverse events that accompany IL-17 pathway blockade. Among IL-23p19 inhibitors, guselkumab (DISCOVER-2 trial) demonstrated ACR20 maintenance of 71–75% at week 52 with minimal serious infection rates in biologic-naïve PsA 43, providing a directly relevant class benchmark; direct head-to-head comparative data with risankizumab in PsA are not available in the retrieved materials. Tildrakizumab, the third approved IL-23p19 inhibitor for psoriasis, achieved PASI 75 in 61–66% of patients in reSURFACE 1/2 versus 48% for etanercept, with a similar low SAE profile 49.
Guideline Positioning and Payer Constraints
Risankizumab occupies guideline-supported positioning across all three specialties. NICE TA596 (August 2019) approved risankizumab for moderate-to-severe plaque psoriasis with a commercial access agreement, while TA803 (July 2022) approved it for active PsA after inadequate DMARD response 2122. The AGA Living Guideline includes risankizumab among recommended biologics for moderate-to-severe CD 23. The 2024 Chinese guideline recommends IL-23 inhibitors—including risankizumab—as equivalent first-line biologic options for plaque psoriasis (Recommendation Strength: A) while giving IL-23 inhibitors a class advantage in patients with TB, hepatitis B, or heart failure risk (Recommendation Strength: C) 27. Ireland's NCPE initially declined reimbursement for risankizumab in UC at the submitted price, though the HSE approved reimbursement in April 2025 after confidential price negotiations, restricting use to patients following at least one lower-cost biologic 35.
In the US, Medicare Advantage coverage for intravenous risankizumab in CD and UC requires prior documentation of failure, contraindication, or intolerance to corticosteroids, immunomodulators, or at least one prior biologic; concurrent use with other biologics is prohibited, and gastroenterologist prescription is mandated 31. Commercial prior authorization policies via CVS Caremark and Express Scripts similarly impose step therapy with prior biologic exposure requirements 3233. A Saudi Arabian budget impact model found that adding risankizumab to the CD treatment mix produced cost savings of 0.45% over five years, though real-world dose escalation increased maintenance treatment costs more than 20% above label-dose projections 36.
Clinical Adoption Implications by Specialty
For dermatologists, risankizumab's every-12-week subcutaneous maintenance schedule offers among the least frequent dosing in its class, and its demonstrated superiority over ustekinumab in phase 2 and phase 3 trials 12 positions it as a preferred agent for patients seeking near-complete or complete skin clearance. Its safety advantage over IL-17 inhibitors in patients with IBD comorbidity or a history thereof is clinically material, given the significant epidemiologic association between psoriasis and IBD 916. For rheumatologists, week-196 durability data from KEEPsAKE 1 and 2 40 support long-term prescribing confidence in both biologic-naïve and biologic-experienced PsA patients, with combination methotrexate permissible but no concurrent biologic use allowed 37. For gastroenterologists, the key adoption driver is the robust IBD-specific pivotal program (ADVANCE, MOTIVATE for CD; NCT03398148 for UC) 341, but the critical adoption barrier is intravenous induction, which demands infusion center integration that many gastroenterology practices without established infusion infrastructure must address prospectively.
Benefit–Risk Conclusion
Risankizumab presents a compelling benefit–risk profile characterized by superior efficacy versus the established IL-12/23 inhibitor ustekinumab in psoriasis 12, durable ACR response maintenance through nearly four years in PsA 40, meaningful induction and maintenance remission rates in CD 34, and statistically significant clinical remission in UC 41—all achieved without emergence of new safety signals or excess serious adverse events versus comparators 48. Its selective IL-23p19 mechanism avoids the IBD exacerbation risk associated with IL-17 inhibitors 8 while offering preserved anti-Candida immune surveillance 6. The primary adoption barriers are operational—intravenous induction capacity requirements for IBD indications, step therapy prior authorization requirements mandating prior biologic exposure in IBD, and real-world dose escalation costs that exceed label projections 3136. Across dermatology, rheumatology, and gastroenterology, guideline alignment is established and strengthening 21222327, and the agent's span across all four major immune-mediated inflammatory disease indications represents a clinically significant opportunity for cross-specialty coordination in patients with overlapping conditions.